Insider Transactions in Q2 2015 at Cvs Health Corp (CVS)
Insider Transaction List (Q2 2015)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2015
|
C David Brown Ii Director |
SELL
Open market or private sale
|
Direct |
10,000
-9.88%
|
$1,020,000
$102.57 P/Share
|
|
May 07
2015
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+50.0%
|
$104,544
$99.36 P/Share
|
|
May 07
2015
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+5.44%
|
$104,544
$99.36 P/Share
|
|
May 07
2015
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,409
+50.0%
|
$139,491
$99.36 P/Share
|
|
May 07
2015
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,868
+4.31%
|
$283,932
$99.36 P/Share
|
|
May 07
2015
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+37.51%
|
$104,544
$99.36 P/Share
|
|
May 07
2015
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
845
+19.62%
|
$83,655
$99.36 P/Share
|
|
May 01
2015
|
C David Brown Ii Director |
SELL
Open market or private sale
|
Direct |
15,000
-12.9%
|
$1,500,000
$100.27 P/Share
|
|
Apr 10
2015
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
17,638
-32.83%
|
$1,799,076
$102.38 P/Share
|
|
Apr 10
2015
|
Andrew Sussman EVP, Clinical Services |
BUY
Exercise of conversion of derivative security
|
Direct |
12,556
+23.67%
|
$615,244
$49.8 P/Share
|
|
Apr 02
2015
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,862
-6.05%
|
$189,924
$102.71 P/Share
|
|
Apr 02
2015
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,596
-10.27%
|
$162,792
$102.71 P/Share
|
|
Apr 02
2015
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
2,394
-7.31%
|
$244,188
$102.71 P/Share
|
|
Apr 02
2015
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,944
-10.99%
|
$2,034,288
$102.71 P/Share
|
|
Apr 02
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,654
-8.2%
|
$474,708
$102.71 P/Share
|
|
Apr 02
2015
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,648
-5.59%
|
$678,096
$102.71 P/Share
|
|
Apr 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
16,637
-21.2%
|
$1,696,974
$102.71 P/Share
|
|
Apr 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,637
+17.49%
|
$748,665
$45.07 P/Share
|
|
Apr 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,989
-6.06%
|
$406,878
$102.71 P/Share
|
|
Apr 02
2015
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,862
-3.15%
|
$189,924
$102.71 P/Share
|
|
Apr 01
2015
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
5,867
+13.56%
|
$598,434
$102.26 P/Share
|
|
Apr 01
2015
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,889
+15.33%
|
$498,678
$102.26 P/Share
|
|
Apr 01
2015
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
3,422
+16.79%
|
$349,044
$102.26 P/Share
|
|
Apr 01
2015
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
3,086
-20.17%
|
$314,772
$102.26 P/Share
|
|
Apr 01
2015
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
8,556
+16.71%
|
$872,712
$102.26 P/Share
|
|
Apr 01
2015
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,115
+14.01%
|
$3,989,730
$102.26 P/Share
|
|
Apr 01
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,778
+14.27%
|
$997,356
$102.26 P/Share
|
|
Apr 01
2015
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
8,556
+4.63%
|
$872,712
$102.26 P/Share
|
|
Apr 01
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,845
+13.5%
|
$698,190
$102.26 P/Share
|
|
Apr 01
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
16,747
-22.55%
|
$1,708,194
$102.26 P/Share
|
|
Apr 01
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,747
+18.4%
|
$569,398
$34.96 P/Share
|
|
Apr 01
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,234
-3.74%
|
$227,868
$102.26 P/Share
|
|
Apr 01
2015
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,422
+16.43%
|
$349,044
$102.26 P/Share
|
|
Apr 01
2015
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-3.19%
|
$183,702
$102.26 P/Share
|
|
Apr 01
2015
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,911
+14.6%
|
$398,922
$102.26 P/Share
|
|
Apr 01
2015
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,029
-4.14%
|
$104,958
$102.26 P/Share
|
|
Apr 01
2015
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
7,334
+20.25%
|
$748,068
$102.26 P/Share
|